Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition.
On March 21, 2018, Sun BioPharma, Inc. (the “Company”) issued a press release providing a business update and announcing financial results for the fourth quarter and full year ended December 31, 2017. The full text of the press release is set forth in Exhibit 99.1 attached hereto and is incorporated by reference in this current report on Form 8-K as if fully set forth herein.
The Company is furnishing the information contained in this report, including Exhibit 99.1, to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01.Financial Statements and Exhibits.
Sun BioPharma, Inc. ExhibitEX-99.1 2 ex_108406.htm EXHIBIT 99.1 ex_108406.htm Exhibit 99.1 Sun BioPharma Provides Business Update and Files Annual Report for 2017 ● Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel to begin patient enrollment early in 2nd Quarter ● Raised $1.3M in private financing MINNEAPOLIS,…To view the full exhibit click
About Sun BioPharma, Inc. (OTCMKTS:SNBP)
Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company’s products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer.